<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806572</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN007AI</org_study_id>
    <secondary_id>NDB01</secondary_id>
    <nct_id>NCT00806572</nct_id>
  </id_info>
  <brief_title>Treatment With hOKT3gamma1(Ala-Ala) in T1DM</brief_title>
  <official_title>Phase II Multiple Dose Treatment of Type 1 Diabetes Mellitus With hOKT3gamma1(Ala-Ala)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to examine the clinical and immunological effects of humanized FcR
      non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop
      this therapy to prevent the immune destruction leading to β cell loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-arm, open-label phase II trial involving 0 or 3 cycles of treatment 6 months
      apart with hOKT3γ1 (Ala-Ala), over the first year of disease in participants with new onset
      T1DM. Each cycle consists of 12 daily doses of hOKT3γ1 (Ala-Ala).

      Participants will be randomized in a ratio of 2:1 to either the experimental arm or the
      control arm and will be stratified by study site.

      To be eligible, participants must be: male or female between 7-30 years of age, diagnosed
      with T1DM within the past 6 weeks, have a body weight ≥26 kg at the time of enrollment and
      have detectable anti-GAD, anti-ICA512/IA-2, or insulin autoantibodies (if the participant has
      been on insulin ≤10 days).

      Participants randomized to the experimental group will start the first cycle of hOKT3γ1
      (Ala-Ala) within 4-8 weeks of T1DM diagnosis. Each participant randomized to the experimental
      group will receive 3 cycles of drug treatment, separated by 6 months each. Each cycle
      consists of 12 days of drug treatment.

      Both groups will undergo the Mixed Meal Stimulated C-Peptide Test and receive blood draws for
      mechanistic studies on the same schedule.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adverse events related to drug lot
  </why_stopped>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-hour C-peptide AUC</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin usage</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hOKT3gamma1(Ala-Ala)</intervention_name>
    <description>3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>teplizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with T1DM within the past 6 weeks

          -  have a body weight ≥26 kg at the time of enrollment

          -  have detectable anti-GAD, anti-ICA512/IA-2, or insulin autoantibodies (if the
             participant has been on insulin ≤10 days).

        Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Prior OKT3 treatment;

          -  Known hypersensitivity to murine products;

          -  Uncompensated heart failure or fluid overload, recent myocardial infarction;

          -  History of epilepsy, cancer, active infection, atopic disease, active Grave's disease,
             cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease,
             cerebrovascular disease, any concurrent autoimmune diseases, asthma;

          -  Any medical condition that in the opinion of the investigator will interfere with safe
             completion of the trial;

          -  Inability to give informed consent;

          -  Prior participation in a clinical trial that could potentially affect diabetes or
             immunologic status;

          -  Participation in a clinical trial within the last 6 weeks;

          -  HIV positive;

          -  Positive for Hepatitis B surface antigen or Anti-Hepatitis C antibody;

          -  Seropositivity for Toxoplasmosis (IgG);

          -  Lymphopenia (&lt;1000 lymphocytes/microliter);

          -  Thrombocytopenia (&lt;150,000/mm3 platelets);

          -  Anemia (Hgb &lt; 10g/dL);

          -  Vaccination with a live virus within the past 6 weeks;

          -  Positive PPD skin test;

          -  Any infectious mononucleosis-like illness within the 3 months prior to enrollment;

          -  Serologic evidence of acute infection with EBV or CMV based on tests listed and as
             defined by the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevan C Herold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naomie Berrie Diabetes Center, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network (ITN) website</description>
  </link>
  <results_reference>
    <citation>Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14.</citation>
    <PMID>19443276</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes, juvenile diabetes, teplizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data access is provided to the public in Participant level data and additional relevant materials are available to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>ITN007AI-NDB01</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN007AIPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is a portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available without charge.Creating an account for ITN TrialShare is free and allows for searching studies of interest.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN007AI-NDB01</doc_id>
      <doc_type>Study protocol synopsis, -navigator, -schedule of events,-data &amp;reports, -specimens et al.</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN007AIPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is a portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available without charge.Creating an account for ITN TrialShare is free and allows for searching studies of interest.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY569</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY569</doc_url>
      <doc_comment>ImmPort study identifier is SDY569. ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts and is available to the Public.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY569</doc_id>
      <doc_type>Study summary, -design, -medications, -demographics, -lab tests, and -files.</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY569</doc_url>
      <doc_comment>ImmPort study identifier is SDY569. ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts and is available to the Public.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

